S
Sara Brett
Researcher at GlaxoSmithKline
Publications - 31
Citations - 2158
Sara Brett is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: T cell & Cytotoxic T cell. The author has an hindex of 15, co-authored 27 publications receiving 1921 citations.
Papers
More filters
Journal ArticleDOI
Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming.
Alfonso Martín-Fontecha,Lindy L. Thomsen,Sara Brett,Craig Gerard,Martin Lipp,Antonio Lanzavecchia,Federica Sallusto +6 more
TL;DR: It is shown in mice that natural killer (NK) cells are rapidly recruited in a CCR7-independent, CXCR3-dependent manner to lymph nodes on stimulation by the injection of mature DCs, and an induced pathway of NK cell migration in antigen-stimulated lymph nodes is identified.
Journal ArticleDOI
Programmed death 1 expression during antiviral treatment of chronic hepatitis B: Impact of hepatitis B e‐antigen seroconversion
A. Evans,Antonio Riva,H. Cooksley,S. Phillips,Smrithi Puranik,Amit C. Nathwani,Sara Brett,Shilpa Chokshi,Nikolai V. Naoumov +8 more
TL;DR: It is demonstrated that in chronic HBV infection, both viremia levels and HBeAg drive PD‐1 expression and resulting T‐cell impairment, and additional immunotherapeutic interventions are needed for restoration of T‐ cell functions.
Journal ArticleDOI
Tumor-immune profiling of murine syngeneic tumor models as a framework to guide mechanistic studies and predict therapy response in distinct tumor microenvironments.
Jun Yu,Sabyasachi Bhattacharya,Niranjan Yanamandra,David J. Kilian,Hong Shi,Sapna Yadavilli,Yuliya V. Katlinskaya,Heather Kaczynski,Michael Conner,William G. Benson,Ashleigh Hahn,Laura M. Seestaller-Wehr,Meixia Bi,Nicholas J. Vitali,Lyuben Tsvetkov,Wendy S. Halsey,Ashley M. Hughes,Christopher M. Traini,Hui Zhou,Junping Jing,Tae Lee,David J. Figueroa,Sara Brett,Christopher B. Hopson,James F. Smothers,Axel Hoos,Roopa Srinivasan +26 more
TL;DR: The tumor microenvironment of four commonly used mouse syngeneic tumor models is characterized and it is proposed each model possesses a unique tumor-immune infiltrate profile that can be probed with immunotherapies to inform on anti-tumor mechanisms and treatment strategies in human tumors with similar profiles.
Journal ArticleDOI
Imiquimod and resiquimod in a mouse model: adjuvants for DNA vaccination by particle-mediated immunotherapeutic delivery.
TL;DR: Two studies in mice suggest that both imiquimod and resquimod may be suitable adjuvants for therapeutic DNA vaccines requiring induction of potent cytotoxic T cell responses.
Journal ArticleDOI
Lipoprotein Access to MHC Class I Presentation During Infection of Murine Macrophages with Live Mycobacteria
Olivier Neyrolles,Keith G. Gould,Marie-Pierre Gares,Sara Brett,Riny Janssen,Peadar O'Gaora,Jean-Louis Herrmann,Marie-Christine Prévost,Emmanuelle Perret,J.E.R. Thole,Douglas B. Young +10 more
TL;DR: Preliminary experiments suggest that class I presentation is more efficient during infection with rapid-growing mycobacteria than with the slow-growing bacillus Calmette-Guérin vaccine strain.